Autoreactive CD8+ T cells play a pivotal role in melanocyte destruction in autoimmune vitiligo. Immunotherapy for melanoma often leads to autoimmune side-effects, among which vitiligo-like depigmentation, indicating that targeting immune checkpoints can break peripheral tolerance against self-antigens in the skin. Therapeutically enhancing immune checkpoint signaling by immune cells or skin cells, making self-reactive T cells anergic, seems a promising therapeutic option for vitiligo. Here, we review the current knowledge on the PD-1/PD-L1 pathway in vitiligo as new therapeutic target for vitiligo therapy.
CITATION STYLE
Willemsen, M., Melief, C. J. M., Bekkenk, M. W., & Luiten, R. M. (2020, November 6). Targeting the PD-1/PD-L1 Axis in Human Vitiligo. Frontiers in Immunology. Frontiers Media S.A. https://doi.org/10.3389/fimmu.2020.579022
Mendeley helps you to discover research relevant for your work.